Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

Entry Deadline Extended To 28 February

Submit your drug development programs for recognition at the 2025 Citeline Awards. The deadline has been extended to 28 Feb.

Star award against curtain background
The Citeline Awards Will Be Held 8 May

In an industry that grapples with high failure rates, it’s important to recognize the successes and the hard work put in by biopharma companies as well as firms supporting those efforts. The Citeline Awards are our way to honor the research and development activity that drives the industry and meets the urgent needs of patients. The Awards are your chance to bring recognition and raise awareness of your innovative R&D work.

The deadline for entries is approaching. The submission fee is $99, which can be applied toward attendance at the event. The extended deadline is 28 February; for anyone needing an extension, please contact Natalia Kay (Natalia.kay@citeline.com).

Guidance on the submission process and details on the criteria for each award are available on the Citeline Awards website. All entries are judged by an independent panel of industry experts.

This year’s categories include:

  • Excellence in Rare Disease Drug Development
  • Most Successful Early Phase Research (Preclinical & Phase I)
  • Champion of Diversity and Inclusion in Clinical Trials
  • Clinical Research Team of the Year – Biotech (Open to Biotech Companies Only)
  • Clinical Research Team of the Year – Pharma (Open to Pharma Companies Only)
  • Clinical Partnership of the Year – Non-CRO
  • CRO Partnership of the Year
  • Innovative Clinical Trial Solutions
  • Industry Achiever
  • Clinical Trial Result of the Year (Open to Pharma & Biotech Companies only)
  • Social/Community Development

The Awards will be presented on 8 May at the Hyatt Regency Boston, Downtown Boston Theater District Hotel. Help us celebrate outstanding contributions to the clinical landscape and gain global industry recognition.

More from Scrip

Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency

 
• By 

Restructuring Edition: Karyopharm is reducing its workforce by 20% as it seeks alternatives to extend its cash runway, but Pacira’s production improvements created efficiency that necessitate an 8% layoff in manufacturing. Jasper, Century, Sage, Leap and Prothena also cut jobs.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

More from